Professor | Xiuwu Bian | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Xiuwu Bian
Contact Information	bianxiuwuoffice@163.com
Language ability	Chinese, English
Province	Chongqing

Upload Avatar (500 x 500)

Name

Xiuwu Bian

Contact Information

bianxiuwuoffice@163.com

Language ability

Chinese, English

Province

Chongqing

University/Lab Affiliation and Title	University of Science and Technology of China
Faculty	Mayo Clinic College of Medicine
Academic Background & Achievements	1981/9-1986/7 Bachelor of Medicine: Third Military Medical University 1986/9-1989/7 Master of Medicine: Third Military Medical University 1991/9-1995/6 Doctor of Medicine: Third Military Medical University Published over 150 SCI papers in renowned journals like Nature, Science, Cell
Work Experience	1989/7-1992/11 - Third Military Medical University - Assistant Lecturer 1992/12-1994/11 - Third Military Medical University - Lecturer 1994/12-1995/12 - Third Military Medical University - Associate Professor 1996/01-1999/08 - Third Military Medical University - Deputy Director, Associate Professor 1999/09-2001/08 - Third Military Medical University - Professor 2001/09-2006/06 - Third Military Medical University - Chief Physician, Professor 2006/07-2017/11 - Third Military Medical University - Department Head, Chief Physician, Professor 2017/12-present - Army Medical University - Department Head, Chief Physician, Professor 2011-present - Director of Key Laboratory of Pathology 2012-present - Director of Key Laboratory of Tumor Immunopathology
Awards	National Science and Technology Progress Award (2012): First Prize Chinese Medical Science Award (2011): First Prize China Anti-Cancer Association Science Award (2010): First Prize Chongqing Natural Science Award (2010): First Prize Chongqing Natural Science Award (2008): First Prize Military Science and Technology Progress Award (1999): Second Prize Ho Leung Ho Lee Foundation Science and Technology Progress Award (2014): Science and Technology Progress Award

University/Lab Affiliation and Title

University of Science and Technology of China

Faculty

Mayo Clinic College of Medicine

Academic Background & Achievements

1981/9-1986/7 Bachelor of Medicine: Third Military Medical University
1986/9-1989/7 Master of Medicine: Third Military Medical University
1991/9-1995/6 Doctor of Medicine: Third Military Medical University
Published over 150 SCI papers in renowned journals like Nature, Science, Cell

Work Experience

1989/7-1992/11 - Third Military Medical University - Assistant Lecturer
1992/12-1994/11 - Third Military Medical University - Lecturer
1994/12-1995/12 - Third Military Medical University - Associate Professor
1996/01-1999/08 - Third Military Medical University - Deputy Director, Associate Professor
1999/09-2001/08 - Third Military Medical University - Professor
2001/09-2006/06 - Third Military Medical University - Chief Physician, Professor
2006/07-2017/11 - Third Military Medical University - Department Head, Chief Physician, Professor
2017/12-present - Army Medical University - Department Head, Chief Physician, Professor
2011-present - Director of Key Laboratory of Pathology
2012-present - Director of Key Laboratory of Tumor Immunopathology

Awards

National Science and Technology Progress Award (2012): First Prize
Chinese Medical Science Award (2011): First Prize
China Anti-Cancer Association Science Award (2010): First Prize
Chongqing Natural Science Award (2010): First Prize
Chongqing Natural Science Award (2008): First Prize
Military Science and Technology Progress Award (1999): Second Prize
Ho Leung Ho Lee Foundation Science and Technology Progress Award (2014): Science and Technology Progress Award

Areas of Focus	Tumor Angiogenesis and Anti-Cancer Drug Research Artificial Intelligence Pathology Diagnosis Tumor Stem Cells and Microenvironment
Publications	COVID-19-associated monocytic encephalitis (CAME): histological and proteomic evidence from autopsy, Zhang PP, He ZC, Yao XH, Tang R, Ma J, Luo T, Zhu C, Li TR, Liu X, Zhang D, Zhang S, Ping YF, Leng L, Bian XW, 2023 Elevated Kir2.1/nuclear N2ICD defines a highly malignant subtype of non-WNT/SHH medulloblastomas, Wang YX, Wu H, Ren Y, Lv S, Ji C, Xiang D, Zhang M, Lu H, Fu W, Liu Q, Yan Z, Ma Q, Miao J, Cai R, Lan X, Wu B, Wang W, Liu Y, Wang DZ, Cao M, He Z, Shi Y, Ping Y, Yao X, Zhang X, Zhang P, Wang JM, Wang Y, Cui Y, Bian XW, 2022 EPHA2 mediates PDGFA activity and functions together with PDGFRA as prognostic marker and therapeutic target in glioblastoma, Gai QJ, Fu Z, He J, Mao M, Yao XX, Qin Y, Lan X, Zhang L, Miao JY, Wang YX, Zhu J, Yang FC, Lu HM, Yan ZX, Chen FL, Shi Y, Ping YF, Cui YH, Zhang X, Liu X, Yao XH, Lv SQ, Bian XW, Wang Y, 2022 ASCL2 Maintains stemness phenotype through ATG9B and sensitizes gliomas to autophagy inhibitor, Wang LH, Yuan Y, Wang J, Luo Y, Lan Y, Ge J, Li L, Liu F, Deng Q, Yan ZX, Liang M, Wei S, Liu XD, Wang Y, Ping YF, Shi Y, Yu SC, Zhang X, Cui YH, Yao XH, Feng H, Luo T, Bian XW, 2022 SIRPγ-expressing cancer stem-like cells promote immune escape of lung cancer via Hippo signaling, Xu C, Jin G, Wu H, Cui W, Wang YH, Manne RK, Wang G, Zhang W, Zhang X, Han F, Cai Z, Pan BS, Hsu CC, Liu Y, Zhang A, Long J, Zou H, Wang S, Ma X, Duan J, Wang B, Liu W, Lan H, Xiong Q, Xue G, Chen Z, Xu Z, Furth ME, Haigh Molina S, Lu Y, Xie D, Bian XW, Lin HK, 2022 A single-cell transcriptomic landscape of the lungs of patients with COVID-19, Wang S, Yao X, Ma S, Ping Y, Fan Y, Sun S, He Z, Shi Y, Sun L, Xiao S, Song M, Cai J, Li J, Tang R, Zhao L, Wang C, Wang Q, Zhao L, Hu H, Liu X, Sun G, Chen L, Pan G, Chen H, Li Q, Zhang P, Xu Y, Feng H, Zhao GG, Wen T, Yang Y, Huang X, Li W, Liu Z, Wang H, Wu H, Hu B, Ren Y, Zhou Q, Qu J, Zhang W, Liu GH, Bian XW, 2021 Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling, Zhang XN, Yang KD, Chen C, He ZC, Wang QH, Feng H, Lv SQ, Wang Y, Mao M, Liu Q, Tan YY, Wang WY, Li TR, Che LR, Qin ZY, Wu LX, Luo M, Luo CH, Liu YQ, Yin W, Wang C, Guo HT, Li QR, Wang B, Chen W, Wang S, Shi Y, Bian XW, Ping YF, 2021

Areas of Focus

Tumor Angiogenesis and Anti-Cancer Drug Research
Artificial Intelligence Pathology Diagnosis
Tumor Stem Cells and Microenvironment

Publications

COVID-19-associated monocytic encephalitis (CAME): histological and proteomic evidence from autopsy, Zhang PP, He ZC, Yao XH, Tang R, Ma J, Luo T, Zhu C, Li TR, Liu X, Zhang D, Zhang S, Ping YF, Leng L, Bian XW, 2023
Elevated Kir2.1/nuclear N2ICD defines a highly malignant subtype of non-WNT/SHH medulloblastomas, Wang YX, Wu H, Ren Y, Lv S, Ji C, Xiang D, Zhang M, Lu H, Fu W, Liu Q, Yan Z, Ma Q, Miao J, Cai R, Lan X, Wu B, Wang W, Liu Y, Wang DZ, Cao M, He Z, Shi Y, Ping Y, Yao X, Zhang X, Zhang P, Wang JM, Wang Y, Cui Y, Bian XW, 2022
EPHA2 mediates PDGFA activity and functions together with PDGFRA as prognostic marker and therapeutic target in glioblastoma, Gai QJ, Fu Z, He J, Mao M, Yao XX, Qin Y, Lan X, Zhang L, Miao JY, Wang YX, Zhu J, Yang FC, Lu HM, Yan ZX, Chen FL, Shi Y, Ping YF, Cui YH, Zhang X, Liu X, Yao XH, Lv SQ, Bian XW, Wang Y, 2022
ASCL2 Maintains stemness phenotype through ATG9B and sensitizes gliomas to autophagy inhibitor, Wang LH, Yuan Y, Wang J, Luo Y, Lan Y, Ge J, Li L, Liu F, Deng Q, Yan ZX, Liang M, Wei S, Liu XD, Wang Y, Ping YF, Shi Y, Yu SC, Zhang X, Cui YH, Yao XH, Feng H, Luo T, Bian XW, 2022
SIRPγ-expressing cancer stem-like cells promote immune escape of lung cancer via Hippo signaling, Xu C, Jin G, Wu H, Cui W, Wang YH, Manne RK, Wang G, Zhang W, Zhang X, Han F, Cai Z, Pan BS, Hsu CC, Liu Y, Zhang A, Long J, Zou H, Wang S, Ma X, Duan J, Wang B, Liu W, Lan H, Xiong Q, Xue G, Chen Z, Xu Z, Furth ME, Haigh Molina S, Lu Y, Xie D, Bian XW, Lin HK, 2022
A single-cell transcriptomic landscape of the lungs of patients with COVID-19, Wang S, Yao X, Ma S, Ping Y, Fan Y, Sun S, He Z, Shi Y, Sun L, Xiao S, Song M, Cai J, Li J, Tang R, Zhao L, Wang C, Wang Q, Zhao L, Hu H, Liu X, Sun G, Chen L, Pan G, Chen H, Li Q, Zhang P, Xu Y, Feng H, Zhao GG, Wen T, Yang Y, Huang X, Li W, Liu Z, Wang H, Wu H, Hu B, Ren Y, Zhou Q, Qu J, Zhang W, Liu GH, Bian XW, 2021
Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling, Zhang XN, Yang KD, Chen C, He ZC, Wang QH, Feng H, Lv SQ, Wang Y, Mao M, Liu Q, Tan YY, Wang WY, Li TR, Che LR, Qin ZY, Wu LX, Luo M, Luo CH, Liu YQ, Yin W, Wang C, Guo HT, Li QR, Wang B, Chen W, Wang S, Shi Y, Bian XW, Ping YF, 2021

Tumor Angiogenesis Anti-Cancer Drug Research Artificial Intelligence Pathology Diagnosis Stem Cells

Junbo Ge - University of Science and Technology of China

Wang Wei - University of Science and Technology of China

Ruipeng Song - University of Science and Technology of China

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us